drugset / Trial / NCT06776250
Study of How Safe and Effective Tarlatamab is in Brain Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2 study to assess how useful study drug tarlatamab is for the treatment of patients with recurrent/refractory oligodendroglioma or astrocytoma with a mutation in the IDH gene.
Timeline
- Start
- 2025-08-18
- Primary completion
- 2028-03-03
- Completion
- 2028-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tarlatamab | Protein / enzyme biologic | 10 mg | — |